1

Supplementary Experimental Procedures
Supplementary text
The karyotype of TREM2 mutant iPSC-lines was assessed with CNV analysis. Both clones of T66Mhet2 had a 47, XYY phenotype (Suppl. Fig1A). Both T66Mhom clones had large areas of loss of heterozygosity on chromosome 6 and 7 (suppl. Fig1B). Clone 3 of the T66Mhom iPSC line featured a heterozygous deletion of approximately 7MB on chromosome 3, starting at position 63348134 and ending at 69934331 (suppl. Fig. 1C ). Karyotype analysis of T66Mhom clone 3 was normal (suppl. Fig. 1D ). The CNV analysis data for all TREM2 mutant lines can be seen in suppl. Table 1 .
Generation of human iPSC-derived microglia-like cells
TREM2 mutant primary fibroblast lines were generated from 4mm skin punch biopsies, which were obtained under informed consent. Ethical permission for this study was obtained from the National Hospital for Neurology and Neurosurgery and the Institute of Neurology joint research ethics committee (study reference 09/H0716/64 for collection of W50C mutant fibroblasts) or approved by the Ethics Committee of Istanbul Faculty of Medicine, Istanbul University (for collection of T66M mutant fibroblasts to Dr Ebba Lohmann). iPSC were generated from fibroblast cultures using 4 factor Sendai virus reprogramming and characterised by RT-PCR for plasmid integration, immunofluorescence for expression of pluripotent markers, and 3-germ layer differentiation and at the NIHR Cambridge Biomedical Research Centre (BRC), human Induced Pluripotent Stem Cells core facility (see Brownjohn et al. 2018) . Karyotypic integrity was assessed by CNV analysis using OmniExpress-24 chips run on the Illumina Infinum platform. CNVs were checked visually on GenomeStudio software. The following control iPSC lines were used: CTRL1 (kindly provided by Dr Selina Wray, UCL Institute of Neurology), ND (called CTRL2 in this paper, from Coriell Institute of Medical Research Biorepository, kindly provided by Dr Rickie Patani, UCL Institute of Neurology), SBAD03 (called CTRL3, from Stembancc), CTRL4 (SFC840, from Stembancc). iPSC colonies were maintained in E8 medium (Life Technologies), and split every 4-5 days using Versene (Lonza). iPSC colonies were differentiated into iPSC-macrophages within 5 passages.
Human iPSC-derived microglia-like cells (iPSC-MGLC) were generated using recently published protocols (van Wilgenburg et al. 2013) , with minor modifications. To generate embryoid bodies at day 0 in vitro (D0), iPSC colonies at 60-80% confluence were dissociated for 4 min with TrypLE (Life Technologies), collected in 10 x the volume of PBS without Ca 2+ /Mg 2+ , pelleted for 3 min at 300 g and resuspended in 1 ml EBDiff medium (E8 medium with 10 µmol ROCK inhibitor (Cambridge Bioscience), 50 ng/ml BMP-4 (Preprotech), 50 ng/ml VEGF, (Preprotech), 20 ng/ml SCF (Miltenyi)). Cells were counted, resuspended in EBDiff medium at 10 5 cells/ml and 100 µl /well (i. Reverse primer: 5'-TCCTTCAGGGCAGGATTTTT-3'), and 50ng genomic DNA. PCR cycling conditions were as follows: Initial denaturation at 95°C for 3 minutes followed by 35 cycles with denaturation at 98°C for 20 sec, annealing at 62°C for 15 sec, extension at 72°C for 30 sec; then a final extension at 72°C for 1 minute. PCR were subsequently visualized on a 1.5% agarose gel to verify the size of the amplicon (533 bp). Finally PCR products were purified using the QIAquick PCR Purification Kit (QIAGEN) and then sequenced commercially (Source Bioscience, Nottingham, UK).
Alignment of sequences and analysis was carried out using SnapGene software (GSL Biotech, version 3.3.3).
Isolation of human blood derived-monocytes
Phlebotomy was performed and blood collected into heparinised tubes. This study was approved by University College London (UCL)/UCL Hospitals Joint Research Ethics Committee (Project ID: 7451/001) and all subjects gave informed written consent. Plasma was separated by incubating the heparinized blood with 3% dextran 500 (Sigma) in an upright position for 60 minutes at room temperature. The leukocytes were pelleted from plasma by centrifugation for 6 minutes at 3 1600 rpm (461g). The cells were resuspended in PBS, layered over Histopaque (Sigma) and centrifuged with low acceleration and brake for 20 minutes at 720g. The resulting peripheral blood mononuclear cell (PBMC) layer was collected and CD14 Microbeads (Miltenyi Biotec) were used to isolate the monocytes, according to the manufacturer's instructions. Blood-derived monocytes were cultured at a density of 5x10 5 per well in X-Vivo medium (Lonza)
supplemented with 100U/ml penicillin/streptomycin (Life Technologies), 1% Glutamax (Life Technologies) and matured into macrophages through continuous culture in 100 ng/ml MCSF (Preprotech) for 6 days.
Quantitative PCR
Cells were lysed and homogenised using RLT buffer (QIAGEN) and total RNA was extracted from cells using an RNeasy minikit (QIAGEN), with an on-column DNase digestion step using RNase-free DNase set (QIAGEN).
Complementary DNAs were generated using the High-Capacity RNA-cDNA kit (Life Technologies), according to the manufacturer's instructions. Quantitative PCR were conducted using TaqMan Universal Mastermix II (ThermoFisher) in the Stratagene Mx3000p qPCR system and MxPro qPCR software. Expression was normalised to GAPDH. The following primers were used (all purchased from Applied Biosystems): 
Immunocytochemistry
Cells were seeded at 2.5x10 4 cells/well, fixed in 4% paraformaldehyde in PBS, washed 1x with PBS, permeabilised with 0.2% Triton X in PBS for 10 minutes at room temperature (RT), blocked in 5% donkey (TREM2 AF1828 antibody) or 5% goat (all other antibodies) serum in PBS for 1h at RT, and incubated in 1% donkey or goat serum in PBS with primary antibody for 2h at RT. For double-immunofluorescence with anti-TREM2 and Golgin antibodies, cells were blocked with 3% bovine serum albumin (BSA) and incubated with 1% BSA in PBS with primary and secondary antibodies, Cells were washed 3x with PBS and incubated for 1h with Alexa Fluor secondary antibodies in 1% serum PBS. Images were taken using a Leica DM550 microscope and LAS AF software (Leica, V2.6.3). For live cell imaging of pHrodo particles, images were taken using a Zeiss Axioskop 2 microscope and Axiovison software (Zeiss, v4.8).
Confocal images were taken with a Zeiss LSM 710 confocal microscope using Zen software (Zeiss, Version 2012), and images processed with Image J1.5 (www.imagej.nih.gov/ij). The following antibodies were used for immunocytochemistry: primary antibodies: mouse anti-CD68 (1:100, DAKO), rabbit anti-iba1 (1:500, WAKO), goat anti-TREM2 AF1828 (10µg/ml, R&D systems), rabbit-anti-TREM2 (D814C, 1:400, Cell Signaling Technology), rabbitanti-Golgin (1:100, Life Technologies). The following secondary antibodies were used: Alexa Fluor donkey anti-goat 568, goat-anti-rabbit 568, goat-anti mouse 488 (all 1:500, Life Technologies).
sTREM2 ELISA
Quantification of sTREM2 from cell culture supernatants was performed using an in house-generated ELISA. MaxiSORP 96 well plates (Nunc) were coated with 1μg/ml of a rat anti-mouse/human monoclonal antibody (R&D Systems; clone 237920) overnight at 4°C. Plates were washed with 1x PBS/0.1% Tween-20 (PBS-T) then blocked with 1% bovine serum albumin (BSA) in 0.1% Tween 20 in PBS (1% BSA/PBS-T; pH 7.4) for 45 minutes at room temperature (RT) with gentle shaking, followed by 3 washes with PBS-T. Cell culture supernatant samples and standards (Recombinant human TREM2-His; Life Technologies; 0 -20ng/ml in 1% BSA/PBS-T) were then incubated for 2h at RT with gentle shaking, followed by 3 washes with PBS-T. For the detection of bound human sTREM2 from the cell culture supernatants, plates were incubated for 1.5h at RT with biotinylated polyclonal goat anti-human TREM2 capture antibody (0.1μg/ml; R&D Systems) diluted in 1% BSA/PBS-T. Plates were subsequently washed 4 times with PBS-T, followed by incubation with a streptavidin-HRP (Invitrogen; 0.1µg/ml) diluted in PBS-T for 45 minutes at RT with gentle shaking. Plates were washed 3 times with PBS-T followed by the addition of a chromogenic substrate solution (TMB) in the dark. The reaction was terminated with the addition of stop solution (0.16M H2SO4) and absorbance was read at 450 nm (Tecan Genios). To further verify sTREM2 secretion a second method was employed, adapted from Kleinberger et al., (2014) . Streptavidin-coated 96-well plates (Meso-Scale discovery (MSD)) were blocked overnight at 4°C in block buffer (0.5% bovine serum albumin (BSA) and 0.05% Tween 20 in PBS (pH 7.4). The plates were next incubated with the biotinylated polyclonal goat anti-human TREM2 capture antibody (0.25µg/ml R&D Systems BAF1828) diluted in block buffer for 1h at room temperature. They were subsequently washed four times with wash buffer (0.05% Tween 20 in PBS) and incubated for 2h at RT with the undiluted cell culture media samples or a standard 6 curve constructed from recombinant human TREM2 protein (4000 -62.5pg/ml Sino Biological Inc 11084-H08H) diluted in assay buffer (0.25% BSA and 0.05% Tween 20 in PBS (pH=7.4). Plates were again washed three times with wash buffer before incubation for 1h at RT with the detector antibody monoclonal mouse anti-human TREM2 antibody (1µg/ml Santa Cruz Biotechnology; B-3, sc373828). After three additional washing steps, plates were incubated with the secondary antibody (SULFO-TAG-labeled anti-mouse secondary antibody, MSD) and incubated for 1h in the dark.
Lastly, plates were washed three times with wash buffer followed by two washing steps in PBS alone. The electrochemical signal was developed by adding MSD Read buffer (1 in 2) and the light emission measured using the MSD SECTOR Imager 6000. The concentration of sTREM2 was calculated using a five-parameter logistic curve fitting method with the MSD Workbench software package. Intra-assay cvs were < 10%, and all samples were measured on the same day using the same reagents. 
